February 9, 2023
Certificate of maximum commercial reliability CRIBIS
We are proud to publish the CERTIFICATE OF MAXIMUM COMMERCIAL RELIABILITY awarded by Cribis. This is the result of the continuous and rigorous commitment that...
November 24, 2022
New authorization IMP (CAPSULES and BIOLOGICAL PRODUCTS)
Fulton received from AIFA a new authorization for the Investigational Medicinal Product (IMP) production of biological products in hard capsules.
September 19, 2022
FULTON AT CPhI 2022
Fulton will be present at the next CPhI Worldwide 2022 in Frankfurt, Germany, from November 1st to 3rd . You can find us at stand...
June 21, 2022
FULTON AT PHARMACEUTICALS MADE IN ITALY
Fulton Medicinali attended “Pharmaceuticals made in Italy” in Ho Chi Minh City (Vietnam). Surely, the best event to further consolidate our presence in the Territory,...
April 14, 2022
INPRO IN SAUDI ARABIA
Our INPRO has successfully completed the registration process in Saudi Arabia, thanks to the collaboration of Pharmart and Arabian Trade House, and will be soon present on...
April 14, 2022
FULTON AT VITAFOODS
Even this year, Fulton will be present at Vitafoods Europe at the Palexpo in Geneva, Switzerland , from October 10th to 12th 2022. To book...
March 18, 2022
FULTON AL DCAT
Fulton will be attending DCAT Week 2022 in NYC, USA, from March 21st to 24th. To book a meeting send an e-mail to fulton@fulton.it
September 1, 2021
FULTON AT CPhI
Fulton will be present at the next CPhI Worldwide 2021 at the Fiera Milano in Milan, Italy, from November 9 to 11. You can find...
September 1, 2021
FULTON AT VITAFOODS
Fulton will be present at the next Vitafoods Europe 2021 at the Palexpo in Geneva, Switzerland , from October 5th to 7th. You can find...
August 30, 2021
LACTOFERRIN FULTON IN UAE
Fulton, with PHARMALINK, have received registration certificate for the products LACTIFOL (B9Ferrina) and FERIKKTO (Fe2Ferrina) in United Arab Emirates (UAE).
July 15, 2021
LACTOFERRIN FULTON IN UKRAINE
Fulton, with VORWARTS PHARMA, have received registration certificate for the products BISFERRO (B9Ferrina) and PORTOFERRO (Fe2Ferrina) in Ukraine.
June 17, 2021
New authorization IMP
Fulton receives from AIFA a new authorization for the Investigational Medicinal Product (IMP) production of the suppositories pharmaceutical form.
February 28, 2021
RARE DISEASES – VIDEO
Between 50% and 75% of people with rare diseases are children like Carlo. We won't stop until rare diseases are even rarer. Link to the...
February 27, 2021
RARE DISEASES
30 million Europeans live with a rare disease: that is 1 in 17 people in Europe. Through continued research and innovation, #WeWontRest until treatments for...
February 26, 2021
RARE DISEASES
30 million Europeans live with a rare disease: that is 1 in 17 people in Europe. Through continued research and innovation, #WeWontRest until treatments for...
February 25, 2021
RARE DISEASES
Clinical trials for rare diseases are growing in Italy. The number of trials in these diseases has grown over time from 66 authorized in 2010...
February 24, 2021
RARE DISEASES
All patients are by definition fragile as they have to deal with the problems and limitations posed by their disease. Certainly rare patients acquire in...
February 23, 2021
RARE DISEASES
According to @DolonLtd, without the OMP Regulation, around 2 million patients would not have seen a therapy become available. #WeWontRest until we meet the needs...
February 23, 2021
COVID-19 EMERGENCY
The Covid-19 emergency teaches us to go further to better face the future. Therefore, improve access to information, diagnosis, screening, home and hospital care and...
February 22, 2021
RARE DISEASES
There are 30 million rare patients in Europe. A disease is defined as rare when it has an incidence of less than 1 case for...
February 22, 2021
RARE DISEASES
Since the EU Orphan Regulation came into force in 2000, the number of orphan medicines increased from 8 to more than 190 today #WeWontRest #RareDiseaseDay...
January 22, 2021
PATENT
ITALY - Fulton Medicinali Invention patent Application No. 102019000000897 (formerly PHF sa) for the prolonged release formulation with gastric permanence based on Nitrofurantoin With this...
January 14, 2021
NOTICE OF PUBLICATION OF APPLICATION
U.S.A. Fulton Medicinali SpA Patent Deposit N ° US2021/0007979 A1 for sublingual tablet comprising Sidenafil Citrate. With this important result, the italian company expands the...